The ‘monopolistic’ brain tumor treatment ‘Temodal’ will face 3-way competition against domestic pharmaceutical products

As a domestic pharmaceutical company entered the MSD’s brain tumor treatment ‘Temodal(temozolomide)’ market, the 3-way competition is expected to be formed.

Temodal was expired in patent on December 2011, but has taken a monopolistic position due to difficulties in its development.(the domestic Temodal market was approximately KRW 8 billion based on the IMS data last year)

Along with the dire...